Our partner site, Fraunhofer IME, will play a key role in Exscalate4CoV (E4C)

Our partner site Fraunhofer IME will play a key role in the EU funded consortium Exscalate4CoV (E4C) to counter the coronavirus pandemic. Fraunhofer IME will be providing the key link between biologists and data scientists in the consortium.

The E4C partners will further examine the efficacy of already marketed and investigational drugs for the treatment of COVID-19 patients.

Fraunhofer IME has specialized in such repurposing efforts in many diseases. The Institute has a repurposing set of 5400 compounds available that have reached clinical use across 600 indications and recently invested in a state of the art High-Content Analysis System for use in profiling the compounds.

Together with scientists from Leuven, Belgium, the Fraunhofer team will analyse these compounds to identify drugs which may either act directly on the virus or strengthen the defence mechanisms of human host cells. "This strategy builds on our deep expertise in repurposing existing marketed drugs towards new indications”, says Dr. Philip Gribbon, Screening Port, Division Translational Medicine, Fraunhofer IME. “We believe it holds great promise of finding an effective drug treatment for COVID-19 infection in the shortest possible timescale.

For more information see here.